Skip to main content
Top
Published in: Pituitary 2/2009

01-06-2009

Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans

Authors: Michelle Lee, Judith Korner

Published in: Pituitary | Issue 2/2009

Login to get access

Abstract

Hypothalamic injury from acquired structural damage due to infiltrative disease, tumor, or their treatment aftereffects frequently results in the development of an obesity syndrome characterized by a rapid, unrelenting weight gain that may be accompanied by severe hyperphagia. Weight gain occurs from the disruption of the normal homeostatic functioning of the hypothalamic centers responsible for controlling satiety and hunger and regulating energy balance with resulting hyperphagia, autonomic imbalance, reduction of energy expenditure, and hyperinsulinemia. Curtailment of weight increase has traditionally been refractory to usual dietary and lifestyle interventions. Pharmacotherapy targeting insulin secretion and augmenting sympathetic output have been attempted to promote weight loss or attenuate weight gain. In addition, case reports suggest that bariatric surgery may be an effective treatment option for these patients. Hormonal deficits are often present, and their management may also have consequences for weight control. Hypothalamic obesity confers significant morbidity and mortality, and there is a need for greater elucidation of its risk factors and pathogenesis so that more effective interventions can be developed.
Literature
3.
go back to reference Bray GA (1993) Commentary on classics of obesity. 4. Hypothalamic obesity. Obes Res 1:325–328 MedlinePubMed Bray GA (1993) Commentary on classics of obesity. 4. Hypothalamic obesity. Obes Res 1:325–328 MedlinePubMed
4.
go back to reference Bruch H (1993) The Frohlich syndrome: report of the original case. 1939. Obes Res 1:329–331 MedlinePubMed Bruch H (1993) The Frohlich syndrome: report of the original case. 1939. Obes Res 1:329–331 MedlinePubMed
5.
go back to reference Bray GA, Gallagher TF Jr (1975) Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a reveiw of the literature. Medicine (Baltimore) 54:301–330 Medline. doi:10.1097/00005792-197507000-00002 Bray GA, Gallagher TF Jr (1975) Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a reveiw of the literature. Medicine (Baltimore) 54:301–330 Medline. doi:10.​1097/​00005792-197507000-00002
6.
go back to reference Bray GA (1984) Syndromes of hypothalamic obesity in man. Pediatr Ann 13:525–536 MedlinePubMed Bray GA (1984) Syndromes of hypothalamic obesity in man. Pediatr Ann 13:525–536 MedlinePubMed
7.
go back to reference Farooqi S, O’Rahilly S (2006) Genetics of obesity in humans. Endocr Rev 27:710–718 MedlinePubMed Farooqi S, O’Rahilly S (2006) Genetics of obesity in humans. Endocr Rev 27:710–718 MedlinePubMed
8.
go back to reference Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007) From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 104:3456–3459 Medline. doi:10.1073/pnas.0611417104 Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007) From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 104:3456–3459 Medline. doi:10.​1073/​pnas.​0611417104
9.
go back to reference Swaab DF, Purba JS, Hofman MA (1995) Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 80:573–579 Medline. doi:10.1210/jc.80.2.573 Swaab DF, Purba JS, Hofman MA (1995) Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 80:573–579 Medline. doi:10.​1210/​jc.​80.​2.​573
10.
go back to reference Swaab DF (1997) Prader-Willi syndrome and the hypothalamus. Acta Paediatr Suppl 423:50–54 MedlinePubMed Swaab DF (1997) Prader-Willi syndrome and the hypothalamus. Acta Paediatr Suppl 423:50–54 MedlinePubMed
11.
go back to reference Anand BK, Brobeck JR (1951) Localization of a “feeding center” in the hypothalamus of the rat. Proc Soc Exp Biol Med 77:323–324 MedlinePubMed Anand BK, Brobeck JR (1951) Localization of a “feeding center” in the hypothalamus of the rat. Proc Soc Exp Biol Med 77:323–324 MedlinePubMed
13.
go back to reference Lee M, Wardlaw SL (2007) The central melanocortin system and the regulation of energy balance. Front Biosci 12:3994–4010 Medline. doi:10.2741/2366 Lee M, Wardlaw SL (2007) The central melanocortin system and the regulation of energy balance. Front Biosci 12:3994–4010 Medline. doi:10.​2741/​2366
14.
go back to reference Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404:661–671 MedlinePubMed Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404:661–671 MedlinePubMed
15.
go back to reference Cone RD (2005) Anatomy and regulation of the central melanocortin system. Nat Neurosci 8:571–578 Medline. doi:10.1038/nn1455 Cone RD (2005) Anatomy and regulation of the central melanocortin system. Nat Neurosci 8:571–578 Medline. doi:10.​1038/​nn1455
16.
go back to reference Roth C, Wilken B, Hanefeld F, Schroter W, Leonhardt U (1998) Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the downregulation of appetite. Eur J Endocrinol 138:89–91 Medline. doi:10.1530/eje.0.1380089 Roth C, Wilken B, Hanefeld F, Schroter W, Leonhardt U (1998) Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the downregulation of appetite. Eur J Endocrinol 138:89–91 Medline. doi:10.​1530/​eje.​0.​1380089
17.
19.
go back to reference Cummings DE, Clement K, Purnell JQ et al (2002) Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 8:643–644 Medline. doi:10.1038/nm0702-643 Cummings DE, Clement K, Purnell JQ et al (2002) Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 8:643–644 Medline. doi:10.​1038/​nm0702-643
20.
go back to reference Tauber M, Conte Auriol F, Moulin P, Molinas C, Delagnes V, Salles JP (2004) Hyperghrelinemia is a common feature of Prader-Willi syndrome and pituitary stalk interruption: a pathophysiological hypothesis. Horm Res 62:49–54 Medline. doi:10.1159/000078862 Tauber M, Conte Auriol F, Moulin P, Molinas C, Delagnes V, Salles JP (2004) Hyperghrelinemia is a common feature of Prader-Willi syndrome and pituitary stalk interruption: a pathophysiological hypothesis. Horm Res 62:49–54 Medline. doi:10.​1159/​000078862
21.
go back to reference Haqq AM, Farooqi IS, O’Rahilly S et al (2003) Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab 88:174–178 Medline. doi:10.1210/jc.2002-021052 Haqq AM, Farooqi IS, O’Rahilly S et al (2003) Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab 88:174–178 Medline. doi:10.​1210/​jc.​2002-021052
22.
go back to reference Goldstone AP, Thomas EL, Brynes AE et al (2004) Elevated fasting plasma ghrelin in Prader-Willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J Clin Endocrinol Metab 89:1718–1726 Medline. doi:10.1210/jc.2003-031118 Goldstone AP, Thomas EL, Brynes AE et al (2004) Elevated fasting plasma ghrelin in Prader-Willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J Clin Endocrinol Metab 89:1718–1726 Medline. doi:10.​1210/​jc.​2003-031118
23.
go back to reference DelParigi A, Tschop M, Heiman ML et al (2002) High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 87:5461–5464 Medline. doi:10.1210/jc.2002-020871 DelParigi A, Tschop M, Heiman ML et al (2002) High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 87:5461–5464 Medline. doi:10.​1210/​jc.​2002-020871
24.
go back to reference Goldstone AP, Patterson M, Kalingag N et al (2005) Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3–36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab 90:2681–2690 Medline. doi:10.1210/jc.2003-032209 Goldstone AP, Patterson M, Kalingag N et al (2005) Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3–36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab 90:2681–2690 Medline. doi:10.​1210/​jc.​2003-032209
25.
go back to reference Kanumakala S, Greaves R, Pedreira CC et al (2005) Fasting ghrelin levels are not elevated in children with hypothalamic obesity. J Clin Endocrinol Metab 90:2691–2695 Medline. doi:10.1210/jc.2004-2175 Kanumakala S, Greaves R, Pedreira CC et al (2005) Fasting ghrelin levels are not elevated in children with hypothalamic obesity. J Clin Endocrinol Metab 90:2691–2695 Medline. doi:10.​1210/​jc.​2004-2175
26.
go back to reference Daousi C, MacFarlane IA, English PJ et al (2005) Is there a role for ghrelin and peptide-YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage? J Clin Endocrinol Metab 90:5025–5030 Medline. doi:10.1210/jc.2004-1874 Daousi C, MacFarlane IA, English PJ et al (2005) Is there a role for ghrelin and peptide-YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage? J Clin Endocrinol Metab 90:5025–5030 Medline. doi:10.​1210/​jc.​2004-1874
27.
go back to reference Martin JM, Konijnendijk W, Bouman PR (1974) Insulin and growth hormone secretion in rats with ventromedial hypothalamic lesions maintained on restricted food intake. Diabetes 23:203–208 MedlinePubMed Martin JM, Konijnendijk W, Bouman PR (1974) Insulin and growth hormone secretion in rats with ventromedial hypothalamic lesions maintained on restricted food intake. Diabetes 23:203–208 MedlinePubMed
28.
go back to reference Hustvedt BE, Lovo A (1972) Correlation between hyperinsulinemia and hyperphagia in rats with ventromedial hypothalamic lesions. Acta Physiol Scand 84:29–33 MedlinePubMedCrossRef Hustvedt BE, Lovo A (1972) Correlation between hyperinsulinemia and hyperphagia in rats with ventromedial hypothalamic lesions. Acta Physiol Scand 84:29–33 MedlinePubMedCrossRef
29.
go back to reference Rohner FDA, Karakash C, Le Marchand Y, Ruf KB, Jeanrenaud B (1977) Immediate effect of lesion of the ventromedial hypothalamic area upon glucose-induced insulin secretion in anaesthetized rats. Diabetalogia 13:239–242. doi:10.1007/BF01219706 Rohner FDA, Karakash C, Le Marchand Y, Ruf KB, Jeanrenaud B (1977) Immediate effect of lesion of the ventromedial hypothalamic area upon glucose-induced insulin secretion in anaesthetized rats. Diabetalogia 13:239–242. doi:10.​1007/​BF01219706
30.
go back to reference Cox JE, Powley TL (1981) Intragastric pair feeding fails to prevent VMH obesity or hyperinsulinemia. Am J Physiol 240:E566–E572 MedlinePubMed Cox JE, Powley TL (1981) Intragastric pair feeding fails to prevent VMH obesity or hyperinsulinemia. Am J Physiol 240:E566–E572 MedlinePubMed
31.
go back to reference Balkan B, Steffens AB, Bruggink JE, Strubbe JH (1991) Hyperinsulinemia and glucose tolerance in obese rats with lesions of the ventromedial hypothalamus: dependence on food intake and route of administration. Metabolism 40:1092–1100 Medline. doi:10.1016/0026-0495(91)90136-K Balkan B, Steffens AB, Bruggink JE, Strubbe JH (1991) Hyperinsulinemia and glucose tolerance in obese rats with lesions of the ventromedial hypothalamus: dependence on food intake and route of administration. Metabolism 40:1092–1100 Medline. doi:10.​1016/​0026-0495(91)90136-K
32.
go back to reference Bray GA, Inoue S, Nishizawa Y (1981) Hypothalamic obesity. The autonomic hypothesis and the lateral hypothalamus. Diabetologia 20(Suppl):366–377 Medline. doi:10.1007/BF00254505 Bray GA, Inoue S, Nishizawa Y (1981) Hypothalamic obesity. The autonomic hypothesis and the lateral hypothalamus. Diabetologia 20(Suppl):366–377 Medline. doi:10.​1007/​BF00254505
33.
go back to reference Bray GA, York DA (1979) Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev 59:719–809 MedlinePubMed Bray GA, York DA (1979) Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev 59:719–809 MedlinePubMed
35.
go back to reference Tokunaga K, Fukushima M, Kemnitz JW, Bray GA (1986) Effect of vagotomy on serum insulin in rats with paraventricular or ventromedial hypothalamic lesions. Endocrinology 119:1708–1711 MedlinePubMed Tokunaga K, Fukushima M, Kemnitz JW, Bray GA (1986) Effect of vagotomy on serum insulin in rats with paraventricular or ventromedial hypothalamic lesions. Endocrinology 119:1708–1711 MedlinePubMed
36.
go back to reference Cox JE, Powley TL (1981) Prior vagotomy blocks VMH obesity in pair-fed rats. Am J Physiol 240:E573–E583 MedlinePubMed Cox JE, Powley TL (1981) Prior vagotomy blocks VMH obesity in pair-fed rats. Am J Physiol 240:E573–E583 MedlinePubMed
37.
go back to reference Inoue S, Bray GA (1977) The effects of subdiaphragmatic vagotomy in rats with ventromedial hypothalamic obesity. Endocrinology 100:108–114 MedlinePubMedCrossRef Inoue S, Bray GA (1977) The effects of subdiaphragmatic vagotomy in rats with ventromedial hypothalamic obesity. Endocrinology 100:108–114 MedlinePubMedCrossRef
38.
go back to reference Berthoud HR, Jeanrenaud B (1979) Acute hyperinsulinemia and its reversal by vagotomy after lesions of the ventromedial hypothalamus in anesthetized rats. Endocrinology 105:146–151 MedlinePubMed Berthoud HR, Jeanrenaud B (1979) Acute hyperinsulinemia and its reversal by vagotomy after lesions of the ventromedial hypothalamus in anesthetized rats. Endocrinology 105:146–151 MedlinePubMed
39.
go back to reference Harz KJ, Muller HL, Waldeck E, Pudel V, Roth C (2003) Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity. J Clin Endocrinol Metab 88:5227–5231 Medline. doi:10.1210/jc.2002-021797 Harz KJ, Muller HL, Waldeck E, Pudel V, Roth C (2003) Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity. J Clin Endocrinol Metab 88:5227–5231 Medline. doi:10.​1210/​jc.​2002-021797
40.
go back to reference Schofl C, Schleth A, Berger D, Terkamp C, von zur Muhlen A, Brabant G (2002) Sympathoadrenal counterregulation in patients with hypothalamic craniopharyngioma. J Clin Endocrinol Metab 87:624–629 Medline. doi:10.1210/jc.87.2.624 Schofl C, Schleth A, Berger D, Terkamp C, von zur Muhlen A, Brabant G (2002) Sympathoadrenal counterregulation in patients with hypothalamic craniopharyngioma. J Clin Endocrinol Metab 87:624–629 Medline. doi:10.​1210/​jc.​87.​2.​624
41.
go back to reference Coutant R, Maurey H, Rouleau S et al (2003) Defect in epinephrine production in children with craniopharyngioma: functional or organic origin? J Clin Endocrinol Metab 88:5969–5975 Medline. doi:10.1210/jc.2003-030552 Coutant R, Maurey H, Rouleau S et al (2003) Defect in epinephrine production in children with craniopharyngioma: functional or organic origin? J Clin Endocrinol Metab 88:5969–5975 Medline. doi:10.​1210/​jc.​2003-030552
42.
go back to reference Fery F, Plat L, van de Borne P, Cogan E, Mockel J (1999) Impaired counterregulation of glucose in a patient with hypothalamic sarcoidosis. N Engl J Med 340:852–856 Medline. doi:10.1056/NEJM199903183401105 Fery F, Plat L, van de Borne P, Cogan E, Mockel J (1999) Impaired counterregulation of glucose in a patient with hypothalamic sarcoidosis. N Engl J Med 340:852–856 Medline. doi:10.​1056/​NEJM199903183401​105
43.
go back to reference Roth CL, Hunneman DH, Gebhardt U, Stoffel-Wagner B, Reinehr T, Muller HL (2007) Reduced sympathetic metabolites in urine of obese patients with craniopharyngioma. Pediatr Res 61:496–501 Medline. doi:10.1203/pdr.0b013e3180332cd6 Roth CL, Hunneman DH, Gebhardt U, Stoffel-Wagner B, Reinehr T, Muller HL (2007) Reduced sympathetic metabolites in urine of obese patients with craniopharyngioma. Pediatr Res 61:496–501 Medline. doi:10.​1203/​pdr.​0b013e3180332cd6​
45.
go back to reference Lustig RH, Rose SR, Burghen GA et al (1999) Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr 135:162–168 Medline. doi:10.1016/S0022-3476(99)70017-X Lustig RH, Rose SR, Burghen GA et al (1999) Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr 135:162–168 Medline. doi:10.​1016/​S0022-3476(99)70017-X
46.
go back to reference Lustig RH, Hinds PS, Ringwald-Smith K et al (2003) Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 88:2586–2592 Medline. doi:10.1210/jc.2002-030003 Lustig RH, Hinds PS, Ringwald-Smith K et al (2003) Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 88:2586–2592 Medline. doi:10.​1210/​jc.​2002-030003
47.
go back to reference Mason PW, Krawiecki N, Meacham LR (2002) The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch Pediatr Adolesc Med 156:887–892 MedlinePubMed Mason PW, Krawiecki N, Meacham LR (2002) The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch Pediatr Adolesc Med 156:887–892 MedlinePubMed
48.
go back to reference Ismail D, O’Connell MA, Zacharin MR (2006) Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. J Pediatr Endocrinol Metab 19:129–134 MedlinePubMed Ismail D, O’Connell MA, Zacharin MR (2006) Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. J Pediatr Endocrinol Metab 19:129–134 MedlinePubMed
49.
50.
go back to reference Pinto G, Bussieres L, Recasens C, Souberbielle JC, Zerah M, Brauner R (2000) Hormonal factors influencing weight and growth pattern in craniopharyngioma. Horm Res 53:163–169 Medline. doi:10.1159/000023562 Pinto G, Bussieres L, Recasens C, Souberbielle JC, Zerah M, Brauner R (2000) Hormonal factors influencing weight and growth pattern in craniopharyngioma. Horm Res 53:163–169 Medline. doi:10.​1159/​000023562
52.
go back to reference Odame I, Reilly JJ, Gibson BE, Donaldson MD (1994) Patterns of obesity in boys and girls after treatment for acute lymphoblastic leukaemia. Arch Dis Child 71:147–149 MedlinePubMedCrossRef Odame I, Reilly JJ, Gibson BE, Donaldson MD (1994) Patterns of obesity in boys and girls after treatment for acute lymphoblastic leukaemia. Arch Dis Child 71:147–149 MedlinePubMedCrossRef
54.
go back to reference Muller HL, Emser A, Faldum A et al (2004) Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J Clin Endocrinol Metab 89:3298–3305 Medline. doi:10.1210/jc.2003-031751 Muller HL, Emser A, Faldum A et al (2004) Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J Clin Endocrinol Metab 89:3298–3305 Medline. doi:10.​1210/​jc.​2003-031751
55.
go back to reference Muller HL, Bueb K, Bartels U et al (2001) Obesity after childhood craniopharyngioma—German multicenter study on pre-operative risk factors and quality of life. Klin Padiatr 213:244–249 Medline. doi:10.1055/s-2001-16855 Muller HL, Bueb K, Bartels U et al (2001) Obesity after childhood craniopharyngioma—German multicenter study on pre-operative risk factors and quality of life. Klin Padiatr 213:244–249 Medline. doi:10.​1055/​s-2001-16855
56.
go back to reference Muller HL, Gebhardt U, Etavard-Gorris N et al (2004) Prognosis and sequela in patients with childhood craniopharyngioma—results of HIT-ENDO and update on KRANIOPHARYNGEOM 2000. Klin Padiatr 216:343–348 Medline. doi:10.1055/s-2004-832339 Muller HL, Gebhardt U, Etavard-Gorris N et al (2004) Prognosis and sequela in patients with childhood craniopharyngioma—results of HIT-ENDO and update on KRANIOPHARYNGEOM 2000. Klin Padiatr 216:343–348 Medline. doi:10.​1055/​s-2004-832339
57.
go back to reference de Vile CJ, Grant DB, Hayward RD, Kendall BE, Neville BG, Stanhope R (1996) Obesity in childhood craniopharyngioma: relation to post-operative hypothalamic damage shown by magnetic resonance imaging. J Clin Endocrinol Metab 81:2734–2737 Medline. doi:10.1210/jc.81.7.2734 de Vile CJ, Grant DB, Hayward RD, Kendall BE, Neville BG, Stanhope R (1996) Obesity in childhood craniopharyngioma: relation to post-operative hypothalamic damage shown by magnetic resonance imaging. J Clin Endocrinol Metab 81:2734–2737 Medline. doi:10.​1210/​jc.​81.​7.​2734
58.
go back to reference Lustig RH, Post SR, Srivannaboon K et al (2003) Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab 88:611–616 Medline. doi:10.1210/jc.2002-021180 Lustig RH, Post SR, Srivannaboon K et al (2003) Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab 88:611–616 Medline. doi:10.​1210/​jc.​2002-021180
59.
go back to reference Daousi C, Dunn AJ, Foy PM, MacFarlane IA, Pinkney JH (2005) Endocrine and neuroanatomic features associated with weight gain and obesity in adult patients with hypothalamic damage. Am J Med 118:45–50 Medline. doi:10.1016/j.amjmed.2004.06.035 Daousi C, Dunn AJ, Foy PM, MacFarlane IA, Pinkney JH (2005) Endocrine and neuroanatomic features associated with weight gain and obesity in adult patients with hypothalamic damage. Am J Med 118:45–50 Medline. doi:10.​1016/​j.​amjmed.​2004.​06.​035
60.
go back to reference Vesely DL (1989) Hypothalamic sarcoidosis: a new cause of morbid obesity. South Med J 82:758–761 MedlinePubMed Vesely DL (1989) Hypothalamic sarcoidosis: a new cause of morbid obesity. South Med J 82:758–761 MedlinePubMed
61.
go back to reference Molina A, Mana J, Villabona C, Fernandez-Castaner M, Soler J (2002) Hypothalamic-pituitary sarcoidosis with hypopituitarism. Long-term remission with methylprednisolone pulse therapy. Pituitary 5:33–36 Medline. doi:10.1023/A:1022153401880 Molina A, Mana J, Villabona C, Fernandez-Castaner M, Soler J (2002) Hypothalamic-pituitary sarcoidosis with hypopituitarism. Long-term remission with methylprednisolone pulse therapy. Pituitary 5:33–36 Medline. doi:10.​1023/​A:​1022153401880
62.
go back to reference Belojevic G, Maric-Zivkovic J (2005) Sarcoidosis and obesity. Med Pregl 58(Suppl 1):44–45 MedlinePubMed Belojevic G, Maric-Zivkovic J (2005) Sarcoidosis and obesity. Med Pregl 58(Suppl 1):44–45 MedlinePubMed
63.
64.
go back to reference Romito LM, Scerrati M, Contarino MF, Iacoangeli M, Bentivoglio AR, Albanese A (2003) Bilateral high frequency subthalamic stimulation in Parkinson’s disease: long-term neurological follow-up. J Neurosurg Sci 47:119–128 MedlinePubMed Romito LM, Scerrati M, Contarino MF, Iacoangeli M, Bentivoglio AR, Albanese A (2003) Bilateral high frequency subthalamic stimulation in Parkinson’s disease: long-term neurological follow-up. J Neurosurg Sci 47:119–128 MedlinePubMed
65.
go back to reference Perlemoine C, Macia F, Tison F et al (2005) Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in Parkinson’s disease. Br J Nutr 93:191–198 Medline. doi:10.1079/BJN20041297 Perlemoine C, Macia F, Tison F et al (2005) Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in Parkinson’s disease. Br J Nutr 93:191–198 Medline. doi:10.​1079/​BJN20041297
66.
go back to reference Macia F, Perlemoine C, Coman I et al (2004) Parkinson’s disease patients with bilateral subthalamic deep brain stimulation gain weight. Mov Disord 19:206–212 Medline. doi:10.1002/mds.10630 Macia F, Perlemoine C, Coman I et al (2004) Parkinson’s disease patients with bilateral subthalamic deep brain stimulation gain weight. Mov Disord 19:206–212 Medline. doi:10.​1002/​mds.​10630
67.
go back to reference Montaurier C, Morio B, Bannier S et al (2007) Mechanisms of body weight gain in patients with Parkinson’s disease after subthalamic stimulation. Brain 130:1808–1818 Medline. doi:10.1093/brain/awm113 Montaurier C, Morio B, Bannier S et al (2007) Mechanisms of body weight gain in patients with Parkinson’s disease after subthalamic stimulation. Brain 130:1808–1818 Medline. doi:10.​1093/​brain/​awm113
68.
go back to reference Lustig RH (2002) Hypothalamic obesity: the sixth cranial endocrinopathy. Endocrinologist 12:210–217 Lustig RH (2002) Hypothalamic obesity: the sixth cranial endocrinopathy. Endocrinologist 12:210–217
69.
go back to reference Lustig RH (2006) Obesity in childhood cancer survivors. Pediatr Endocrinol Rev 3(Suppl 2):306–311 Lustig RH (2006) Obesity in childhood cancer survivors. Pediatr Endocrinol Rev 3(Suppl 2):306–311
70.
go back to reference Ahmet A, Blaser S, Stephens D, Guger S, Rutkas JT, Hamilton J (2006) Weight gain in craniopharyngioma—a model for hypothalamic obesity. J Pediatr Endocrinol Metab 19:121–127 MedlinePubMed Ahmet A, Blaser S, Stephens D, Guger S, Rutkas JT, Hamilton J (2006) Weight gain in craniopharyngioma—a model for hypothalamic obesity. J Pediatr Endocrinol Metab 19:121–127 MedlinePubMed
71.
go back to reference Srinivasan S, Ogle GD, Garnett SP, Briody JN, Lee JW, Cowell CT (2004) Features of the metabolic syndrome after childhood craniopharyngioma. J Clin Endocrinol Metab 89:81–86 Medline. doi:10.1210/jc.2003-030442 Srinivasan S, Ogle GD, Garnett SP, Briody JN, Lee JW, Cowell CT (2004) Features of the metabolic syndrome after childhood craniopharyngioma. J Clin Endocrinol Metab 89:81–86 Medline. doi:10.​1210/​jc.​2003-030442
72.
go back to reference Bulow B, Attewell R, Hagmar L, Malmstrom P, Nordstrom CH, Erfurth EM (1998) Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence. J Clin Endocrinol Metab 83:3897–3904 Medline. doi:10.1210/jc.83.11.3897 Bulow B, Attewell R, Hagmar L, Malmstrom P, Nordstrom CH, Erfurth EM (1998) Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence. J Clin Endocrinol Metab 83:3897–3904 Medline. doi:10.​1210/​jc.​83.​11.​3897
73.
go back to reference Reeves AG, Plum F (1969) Hyperphagia, rage, and dementia accompanying a ventromedial hypothalamic neoplasm. Arch Neurol 20:616–624 MedlinePubMed Reeves AG, Plum F (1969) Hyperphagia, rage, and dementia accompanying a ventromedial hypothalamic neoplasm. Arch Neurol 20:616–624 MedlinePubMed
74.
go back to reference Cauble MS, Mack-Shipman L, Schaefer GB, Balakrishnan S, Larsen JL (2001) Idiopathic hypothalamic dysfunction with precocious puberty and adipsic hypernatremia first presenting in adolescence. J Pediatr Endocrinol Metab 14:1163–1167 MedlinePubMed Cauble MS, Mack-Shipman L, Schaefer GB, Balakrishnan S, Larsen JL (2001) Idiopathic hypothalamic dysfunction with precocious puberty and adipsic hypernatremia first presenting in adolescence. J Pediatr Endocrinol Metab 14:1163–1167 MedlinePubMed
75.
go back to reference Gobatto CA, Mello MA, Souza CT, Ribeiro IA (2002) The monosodium glutamate (MSG) obese rat as a model for the study of exercise in obesity. Res Commun Mol Pathol Pharmacol 111:89–101 MedlinePubMed Gobatto CA, Mello MA, Souza CT, Ribeiro IA (2002) The monosodium glutamate (MSG) obese rat as a model for the study of exercise in obesity. Res Commun Mol Pathol Pharmacol 111:89–101 MedlinePubMed
76.
go back to reference Scomparin DX, Grassiolli S, Marcal AC, Gravena C, Andreazzi AE, Mathias PC (2006) Swim training applied at early age is critical to adrenal medulla catecholamine content and to attenuate monosodium L-glutamate-obesity onset in mice. Life Sci 79:2151–2156 Medline. doi:10.1016/j.lfs.2006.07.012 Scomparin DX, Grassiolli S, Marcal AC, Gravena C, Andreazzi AE, Mathias PC (2006) Swim training applied at early age is critical to adrenal medulla catecholamine content and to attenuate monosodium L-glutamate-obesity onset in mice. Life Sci 79:2151–2156 Medline. doi:10.​1016/​j.​lfs.​2006.​07.​012
77.
go back to reference Martins AC, Souza KL, Shio MT, Mathias PC, Lelkes PI, Garcia RM (2004) Adrenal medullary function and expression of catecholamine-synthesizing enzymes in mice with hypothalamic obesity. Life Sci 74:3211–3222 Medline. doi:10.1016/j.lfs.2003.10.034 Martins AC, Souza KL, Shio MT, Mathias PC, Lelkes PI, Garcia RM (2004) Adrenal medullary function and expression of catecholamine-synthesizing enzymes in mice with hypothalamic obesity. Life Sci 74:3211–3222 Medline. doi:10.​1016/​j.​lfs.​2003.​10.​034
78.
go back to reference Muller HL, Heinrich M, Bueb K et al (2003) Perioperative dexamethasone treatment in childhood craniopharyngioma—influence on short-term and long-term weight gain. Exp Clin Endocrinol Diabetes 111:330–334 Medline. doi:10.1055/s-2003-42722 Muller HL, Heinrich M, Bueb K et al (2003) Perioperative dexamethasone treatment in childhood craniopharyngioma—influence on short-term and long-term weight gain. Exp Clin Endocrinol Diabetes 111:330–334 Medline. doi:10.​1055/​s-2003-42722
79.
go back to reference Tiosano D, Eisentein I, Militianu D, Chrousos GP, Hochberg Z (2003) 11 beta-Hydroxysteroid dehydrogenase activity in hypothalamic obesity. J Clin Endocrinol Metab 88:379–384 Medline. doi:10.1210/jc.2002-020511 Tiosano D, Eisentein I, Militianu D, Chrousos GP, Hochberg Z (2003) 11 beta-Hydroxysteroid dehydrogenase activity in hypothalamic obesity. J Clin Endocrinol Metab 88:379–384 Medline. doi:10.​1210/​jc.​2002-020511
80.
go back to reference Friedberg M, Zoumakis E, Hiroi N, Bader T, Chrousos GP, Hochberg Z (2003) Modulation of 11 beta-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab 88:385–393 Medline. doi:10.1210/jc.2002-020510 Friedberg M, Zoumakis E, Hiroi N, Bader T, Chrousos GP, Hochberg Z (2003) Modulation of 11 beta-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab 88:385–393 Medline. doi:10.​1210/​jc.​2002-020510
81.
go back to reference Fernandes JK, Klein MJ, Ater JL, Kuttesch JF, Vassilopoulou-Sellin R (2002) Triiodothyronine supplementation for hypothalamic obesity. Metabolism 51:1381–1383 Medline. doi:10.1053/meta.2002.35591 Fernandes JK, Klein MJ, Ater JL, Kuttesch JF, Vassilopoulou-Sellin R (2002) Triiodothyronine supplementation for hypothalamic obesity. Metabolism 51:1381–1383 Medline. doi:10.​1053/​meta.​2002.​35591
82.
go back to reference Hoffman AR, Kuntze JE, Baptista J et al (2004) Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2048–2056 Medline. doi:10.1210/jc.2003-030346 Hoffman AR, Kuntze JE, Baptista J et al (2004) Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2048–2056 Medline. doi:10.​1210/​jc.​2003-030346
83.
go back to reference Schoenle EJ, Zapf J, Prader A, Torresani T, Werder EA, Zachmann M (1995) Replacement of growth hormone (GH) in normally growing GH-deficient patients operated for craniopharyngioma. J Clin Endocrinol Metab 80:374–378 Medline. doi:10.1210/jc.80.2.374 Schoenle EJ, Zapf J, Prader A, Torresani T, Werder EA, Zachmann M (1995) Replacement of growth hormone (GH) in normally growing GH-deficient patients operated for craniopharyngioma. J Clin Endocrinol Metab 80:374–378 Medline. doi:10.​1210/​jc.​80.​2.​374
84.
go back to reference Geffner M, Lundberg M, Koltowska-Haggstrom M et al (2004) Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database). J Clin Endocrinol Metab 89:5435–5440 Medline. doi:10.1210/jc.2004-0667 Geffner M, Lundberg M, Koltowska-Haggstrom M et al (2004) Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database). J Clin Endocrinol Metab 89:5435–5440 Medline. doi:10.​1210/​jc.​2004-0667
85.
go back to reference Verhelst J, Kendall-Taylor P, Erfurth EM et al (2005) Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab 90:4636–4643 Medline. doi:10.1210/jc.2005-0185 Verhelst J, Kendall-Taylor P, Erfurth EM et al (2005) Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab 90:4636–4643 Medline. doi:10.​1210/​jc.​2005-0185
86.
go back to reference Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M (2004) A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28:1399–1410 Medline. doi:10.1038/sj.ijo.0802783 Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M (2004) A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28:1399–1410 Medline. doi:10.​1038/​sj.​ijo.​0802783
87.
go back to reference Bray GA, Hollander P, Klein S et al (2003) A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 11:722–733 MedlinePubMedCrossRef Bray GA, Hollander P, Klein S et al (2003) A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 11:722–733 MedlinePubMedCrossRef
88.
89.
go back to reference Despres JP (2007) The endocannabinoid system: a new target for the regulation of energy balance and metabolism. Crit Pathw Cardiol 6:46–50 MedlinePubMed Despres JP (2007) The endocannabinoid system: a new target for the regulation of energy balance and metabolism. Crit Pathw Cardiol 6:46–50 MedlinePubMed
90.
go back to reference Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761–775 Medline. doi:10.1001/jama.295.7.761 Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761–775 Medline. doi:10.​1001/​jama.​295.​7.​761
91.
go back to reference Muller HL, Gebhardt U, Wessel V et al (2007) First experiences with laparoscopic adjustable gastric banding (LAGB) in the treatment of patients with childhood craniopharyngioma and morbid obesity. Klin Padiatr 219:323–325 Medline. doi:10.1055/s-2007-985848 Muller HL, Gebhardt U, Wessel V et al (2007) First experiences with laparoscopic adjustable gastric banding (LAGB) in the treatment of patients with childhood craniopharyngioma and morbid obesity. Klin Padiatr 219:323–325 Medline. doi:10.​1055/​s-2007-985848
92.
go back to reference Inge TH, Pfluger P, Zeller M et al (2007) Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nat Clin Pract Endocrinol Metab 3:606–609 Medline. doi:10.1038/ncpendmet0579 Inge TH, Pfluger P, Zeller M et al (2007) Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nat Clin Pract Endocrinol Metab 3:606–609 Medline. doi:10.​1038/​ncpendmet0579
Metadata
Title
Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans
Authors
Michelle Lee
Judith Korner
Publication date
01-06-2009
Publisher
Springer US
Published in
Pituitary / Issue 2/2009
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-008-0096-4

Other articles of this Issue 2/2009

Pituitary 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.